Management of Hand and Nail Psoriasis
Disease Severity Classification
- Hands are designated as “vulnerable areas” that mandate systemic therapy regardless of body‑surface‑area involvement, reflecting their severe classification. [@1]
- Hand involvement produces disproportionate functional impairment and quality‑of‑life loss compared with other sites. [@1]
First‑Line Therapy for Mild Disease (≤ 3 Nails Affected)
- Apply high‑potency topical corticosteroid (clobetasol 0.05 % cream) under occlusion to the affected hand and nail unit. [@4]
- Add calcipotriene (vitamin D analogue) to improve nail thickness, hyperkeratosis, and onycholysis. [@4]
- Do not combine calcipotrine with salicylic acid; the acidic pH inactivates calcipotriene. [@4]
- If no improvement after 4 weeks, intralesional triamcinolone acetonide 5–10 mg/cc injected into the nail matrix is highly effective for ≤ 3 affected nails. [@4]
- Topical agents alone have limited efficacy for severe nail disease because of poor nail‑plate penetration. [@4]
First‑Line Therapy for Moderate‑to‑Severe Disease (> 3 Nails or Functional Impairment)
- Biologic disease‑modifying antirheumatic drugs (DMARDs) are the most effective option and should be initiated as first‑line therapy. [@4]
Biologic Options and Evidence Strength
| Biologic Class | Representative Agents | Evidence Highlights | Strength / Grade |
|---|---|---|---|
| IL‑17 inhibitors | Secukinumab, Ixekizumab | May provide superior short‑term nail‑psoriasis clearance. | High (based on comparative trials) |
| TNF inhibitors | Adalimumab, Etanercept, Infliximab | Adalimumab: 47 % achieve mNAPSI 75 at 26 weeks; 49 % reach clear or minimal disease. Etanercept: 50 mg twice weekly for 12 weeks, then 50 mg weekly maintenance. | Grade A (AA Dermatology) |
| IL‑12/23 inhibitor | Ustekinumab | Median NAPSI improvement: 42.5 % (week 16), 86.3 % (week 28), 100 % (week 40). Dosing: 45 mg (<100 kg) or 90 mg (≥100 kg) at weeks 0, 4, then q12 weeks; can be intensified to 90 mg for all or q8 weeks for inadequate response. | Grade A (AA Dermatology) |
- Etanercept efficacy may be reduced in patients with high body‑mass index. [@6]
Combination Therapy Strategies
- Etanercept combined with high‑potency topical corticosteroids (with or without vitamin D analogue) receives a Grade A recommendation. [@2]
- Etanercept plus methotrexate carries a Grade B recommendation. [@2]
- Ustekinumab can be paired with topical corticosteroids (with or without vitamin D analogue) to enhance outcomes. [@7]
Alternative Systemic Options (Second‑Line)
- Acitretin 0.2–0.4 mg/kg/day for patients unsuitable for biologics. [@4]
- Methotrexate 15 mg/week, especially when extensive skin disease co‑exists. (Evidence from rheumatology literature). [@6]
- Cyclosporine limited to ≤ 12 consecutive months due to cumulative nephrotoxicity. [@4]
- Apremilast as an oral second‑line agent. [@4]
Critical Clinical Pitfalls to Avoid
- Systemic corticosteroid monotherapy is contraindicated because it can precipitate pustular or erythrodermic flares during tapering. [@4]
- Calcipotriene must never be mixed with salicylic acid; the acidic environment inactivates the vitamin D analogue. [@4]
- Relying solely on topical therapy for severe nail disease is ineffective due to poor nail‑plate penetration. [@4]
- Tazarotene is teratogenic; effective contraception is required for women of reproductive potential. [@4]
Psoriatic Arthritis Considerations
- When psoriatic arthritis co‑exists, biologic DMARDs are strongly recommended as first‑line therapy. [@4]
- Etanercept is endorsed (Grade A) for plaque psoriasis of any severity with significant psoriatic arthritis. [@2]
- Ustekinumab is endorsed (Grade A) for any severity psoriasis with psoriatic arthritis. [@7]
- Hand and nail involvement heightens the risk of progressive psoriatic arthritis, supporting earlier initiation of systemic therapy. [@4]